|
THE FEMALE HEALTH COMPANY REPORTS:
Chicago-based Female
Health Company Battles
African Aids crisis World
AIDS Day marks expansion of successful Female Condom program in Namibia
CHICAGO, Nov. 27, 2000 – Chicago’s concrete jungle may be worlds away from the African continent, but the two places have something in common. The Windy City is home to the only U.S. company leading the way in HIV/AIDS prevention from a woman’s perspective. “Women
in sub-Saharan Africa and other developing world countries are at
particular risk for HIV infection,” said Mary Ann Leeper, Ph.D.,
president of The Female Health Company (OTC BB: FHCO.OB).
“The Female Condom remains the only product controlled by women
that helps prevent STDs, including HIV/AIDS and pregnancy.” On
World AIDS Day 2000, this Dec. 1, The Female Health Company will add
another success story in its effort to stop the progression of the AIDS
epidemic in the developing world. Namibia, the southern African country
with the world’s third highest incidence of HIV/AIDS, will expand Female
Condom education and distribution as part of its national HIV/AIDS
prevention strategy.. “Together
with organizations, such as UNAIDS, and governments of developing world
countries, the Female Health Company has introduced Female Condom programs
in more than 50 countries around the world,” said Dr.
Leeper. “Namibia is a
particularly triumphant story because women demanded the Female Condom,
prompting the newly formed Ministry of Women Affairs and Child Development
and the Ministry of Health and Social Service to collaborate with private
organizations and others to implement a strong HIV-prevention program.” With
support from UNAIDS and the Female Health Company, Namibia first conducted
a Female Condom pilot program in five regions of the country with the
highest HIV prevalence. Female
Condom uptake exceeded expectations with pilot program participants
requesting additional Female Condoms.
Most important, participants began to teach their friends and
neighbors about the Female Condom, sparking further interest.
The pilot study also found that men were willing and enthusiastic
to participate and sometimes initiate Female Condom use. Planning
for the pilot program and expanded national strategy was guided by the
recent UNAIDS and WHO publication, The Female Condom:
A Guide for Planning and Programming.
The Guide helps health professionals and community
organizations design, implement and monitor the introduction of the Female
Condom in a range of different settings.
Reflecting field experiences from projects all over the world, the Guide
demonstrates how to integrate the Female Condom into existing reproductive
health programs, train health providers, communicate to women and men
about the Female Condom and facilitate the use of the product. Namibia
isn’t the only country or Africa the only continent where Female Condom
programming is helping to reduce HIV infection.
In Brazil, protected sex acts increased 34 percent when the Female
Condom was introduced and both women and men were educated about its use. Thailand saw similar results. UNAIDS
supported studies show that when the Female Condom is available as an
option, there is a significant reduction in the incidence of sexually
transmitted disease (STD) compared to when only the male condom is
available. Additional research shows that the inclusion of the Female
Condom into prevention programs can be cost saving as it reduces the
number of unprotected sexual acts and the incidence of STDs. Programs
similar to Namibia’s will be implemented during the coming year. On Nov. 10, 2000, the governments of the United Kingdom and
the Netherlands announced that they would contribute $76 million to the
United Nations Population Fund (UNFPA) to purchase male and female
condoms, other methods of contraception, obstetric and gynecological
equipment, and drugs for the treatment of sexually transmitted disease in
the world’s poorest countries. The
Female Condomä is the only available product controlled by a
woman that protects against sexually transmitted diseases, including
HIV/AIDS, and pregnancy. It
is made of polyurethane, which is strong and unlikely to rip or tear
during use or to cause allergic reactions.
The Female Health Company, based in Chicago, owns certain worldwide
rights to The Female Condomä,
including patents that have been issued in the United States, United
Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of
China, Canada, New Zealand, South Korea and Australia.
The company manufactures the Female Condom in a state-of-the-art
facility in London, England. “Safe
Harbor” Statement under the Private Securities Litigation Reform Action
of 1995:
The statements in this release which are not historical fact are
forward-looking statements based upon the Company’s current plans and
strategies, and reflect the Company’s current assessment of the risks
and uncertainties related to its business, including such things as
product demand and market acceptance; the economic and business
environment and the impact of governmental regulations, both in the United
States and abroad; the effects of competitive products and pricing
pressures; currency risks; capacity; efficiency and supply constraints;
and other risks detailed in the Company’s press releases, shareholder
communication and Securities and Exchange Commission filings.
Actual events affecting the Company and the impact of such events
on the Company’s operations may vary from those currently anticipated. ###
For more information about the Female Health
Company, dial toll-free via fax,
Investor Contact
Product Contact
Media Contact William R. Gargiulo, Jr.
Mary Ann Leeper, Ph.D. Yvette
Anne Venable 231.526.1244
312.280.1119 x223
312.397.6036
|